This 10-Bagger's Still Got Legs

• By the tickerspy.com Staff
• On 12:31 pm EDT, Tuesday September 8, 2009

More news from Opexa (NASDAQ: OPXA - News) sent shares higher by 170%.

Opexa shares more than doubled on Tuesday after the company announced that more than 83% of the patients in its multiple sclerosis drug study were relapse-free after a full year. Typically patients suffering from the initial stage of the progressive disease suffer from unpredictable relapses followed by months or years of new symptoms, according to a Reuters report.

A month ago we covered Opexa's deal with Novartis (NYSE: NVS - News), which sent shares flying by over 400%. The stock is currently trading at more than 12 times its value six months ago.

As a whole, the Stem Cell Stocks Index is mixed today, though Opexa's news is carrying it higher by 9.3%. The Index is now ahead of the S&P 500 by 2.7% over the last month.

Thermogenesis (NASDAQ: KOOL - News) and Pluristem Therapeutics (NASDAQ: PSTI - News) are also trading higher to start the week following the Labor Day holiday.

Meanwhile Osiris (NASDAQ: OSIR - News) is down by -30% after its Prochymal drug failed in two late-stage studies. Prochymal didn't show any benefit over the dummy drug used in both of its Graft vs Host Disease (GvHD) trials, according to Reuters. Last week we noted an analyst's call that Opexa investors were betting on a coin flip, and Adam Feuerstein at The Street.com said, "It's no surprise" that the Prochymal studies came up short. Investors bold enough to hold the volatile stock over the holiday weekend are paying for it today.

Elsewhere in the stem cell industry StemCells (NASDAQ: STEM - News), Geron (NASDAQ: GERN - News), and Cytori (NASDAQ: CYTX - News) are all in negative territory, but by less than -2.5%.

Investors interested in capitalizing on further developments in the stem cell research sector should keep a close eye on the Stem Cell Stocks Index at tickerspy.com. The Index has now broken into the top-50 performing tickerspy Indexes over the last month, up by 5%.

Fun and informative, tickerspy.com is a free investing website where you can track multiple stock portfolios and compare against 250 proprietary Indexes tracking themes from nanotech to agriculture to precious metals. Best of all, tickerspy.com lets you spy on the portfolios of nearly 3,000 Wall Street institutions and hedge funds and see graphs of their performance. Try tickerspy.com today and find out how you stack up against investing legends like Warren Buffett!

Buzz up!